Company Details
  • Conbott Pharmtech Co.,Ltd.

  •  [Zhejiang,China]
  • Business Type:Manufacturer
  • Main Mark: Africa , Americas , Asia , Caribbean , East Europe , Europe , Middle East , North Europe , Oceania , Other Markets , West Europe , Worldwide
  • Exporter:71% - 80%
  • Certs:COS, ISO9001, ISO14010, FDA
  • Description:Raf Inhibitors,Raf Inhibitors Study,Raf Inhibitors Clinical Trials
Conbott Pharmtech Co.,Ltd. Raf Inhibitors,Raf Inhibitors Study,Raf Inhibitors Clinical Trials
Home > Products > Inhibitors > Raf Inhibitors
Title
  • Title
  • All
Online Service
http://www.conbottpharm.comScan to visit

Raf Inhibitors

Product categories of Raf Inhibitors, we are specialized manufacturers from China, Raf Inhibitors, Raf Inhibitors Study suppliers/factory, wholesale high-quality products of Raf Inhibitors Clinical Trials R & D and manufacturing, we have the perfect after-sales service and technical support. Look forward to your cooperation!
View: List Grid
Anti Tumor Drugs Sorafenib Tosylate, CAS 475207-59-1
Anti Tumor Drugs Sorafenib Tosylate, CAS 475207-59-1

Model No. : 475207-59-1
Unit Price : 1

Leading manufacturer and supplier of chemicals Cas 475207-59-1 Sorafenib Tosylate in China. We develop, produce and distribute high quality pharmaceuticals, intermediates, special chemicals and other fine chemicals. Sorafenib Tosylate Cas...

China Manufacturer of Raf Inhibitors

China Raf Inhibitors Suppliers

Raf is an important signal transduction factor used in the mitogen- activated protein kinase MAPK pathway , undertake upstream Ras signal, transmitted to the downstream MEK / ERK, affecting the growth and differentiation of cells. MAPK pathway is one of the most important signals in the human body , it plays a very important role in the cytoplasmic activity and regulation of gene expression . if overexpression or mutation of subtype BRAF in the MAPK signaling pathway of Raf family , it may induce tumor development and progression. Currently Sorafenib is the most popular drug in Raf inhibitor family, has entered the fast-track passage of drug administration , is the first approved for clinical application of a multi-target targeted therapies in the world . It is used for the treatment of liver cancer cells, kidney cancer cells, locally recurrent or metastatic , progressive differentiated thyroid patients. With the gradual deepening of the study , there will be born a greater variety of more efficacy Raf Inhibitors Drug.
Conbottpharm could give you:
1. Best quality in your requirement
2. Competitive price in China market
3. Mature Technical support
4. Professional logistic support
All we want is win-win business. Send yr. inquiries, you will get it!
Copyright © 2018 Conbott Pharmtech Co.,Ltd. All rights reserved.
Communicate with Supplier?Supplier
Tommy Mr. Tommy
What can I do for you?